Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 69Carcinoma, Intraductal, Noninfiltrating 9Breast Carcinoma In Situ 6Breast Neoplasms, Male 5Neoplasms 3Neoplasm Metastasis 3Urinary Bladder Neoplasms 2Inflammatory Breast Neoplasms 2Sleep Wake Disorders 1Risk Reduction Behavior 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Obesity 1Newly Diagnosed Hormone Positive Clinical Stage 1 or 2 Breast Cancer 1Mastodynia 1Glioma 1Fibrocystic Breast Disease 1Fibroadenoma 1Fatigue 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Disease Progression 1Desmoid Tumors 1Cystic Fibrosis 1Cystadenocarcinoma, Serous 1Carcinoma, Ovarian Epithelial 1Carcinoma, Lobular 1Bulbo-Spinal Atrophy, X-Linked 1Breast Cancer Metastatic 1

Interventions

pembrolizumab 1eicosapentaenoic acid ethyl ester 1eicosapentaenoic acid ethanolamide 1binimetinib 1Vorinostat 1Tamoxifen 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Letrozole 1Imatinib Mesylate 1Fulvestrant 1Dasatinib 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Anatomic Stage IV Breast Cancer AJCC v8 × Tamoxifen × Clear all
NCT04190056 2023-08-31

Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer

University of California, San Francisco

Phase 2 Terminated
1 enrolled 4 charts
Breast

Anatomic Stage IV Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡